



Fact sheet 12/2020

CALL FOR PROPOSALS

Title

Innovative Medicine Initiative 2 – Call 23

Reference

H2020-JTI-IMI2-2020-23-two-stage

Budget

47,7 million euro



Introduction

The Innovative Medicines Initiative 2 (IMI2) Joint Undertaking is a public-private partnership between the European Commission and EFPIA (the European Federation of Pharmaceutical Industry and Associations), implemented through public-private consortia to carry out research or other actions, where the EU provides funding and EFPIA and other members matching the EU funding with their own contributions. IMI2 supports the development and implementation of pre-competitive research and innovation actions and any relevant accompanying measures to improve European citizens' health and well-being.

Objective of the call

The present calls will fund one Research and Innovation Action in the following topics:

Topic 1: Returning Clinical Trial Data to study participants within a GDPR compliant and approved ethical framework. Scope: align local and pan-European implementations and best practice for handling personal data protection regulations to foster the harmonisation of the legal framework applicable to medical research; to deliver a pan-European prototype process to return clinical trial data to study participants, building on previous and ongoing EU-level activities on citizen-centric access to health records. Duration: 48 months. Grant: 3,2 million euro.

Topic 2: Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance (AMR). Scope: develop a framework for setting up antimicrobial resistance (AMR)-focused economic evaluations of vaccines and mAbs. The challenges include a measurement of the present rate of growth of AMR, its main drivers, its health and economic



consequences, and which vaccines and mAbs might have the best chance of reducing the rate of AMR growth and the related health and economic consequences. Duration: 60 months: Grant: 6,5 million euro.

Topic 3: A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases. Scope: create a set of agreed principles to enable sharing and access to data and samples; establish a network that can house high quality data and samples, which could have federated and centralised elements; establish fair and transparent governance and processes specifically to enable sharing and access to data and samples; test them with the defined case studies and apply the learnings to fine-tune processes and use the outcomes to grow the platform. Duration: 60 months: Grant: 9,6 million euro.

Topic 4: Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence. Scope: establish guideline-based decision support and platform solutions to generate knowledge discovery for breast, lung and prostate cancer with applicability to other indications, in several European (EU member states and H2020 associated countries) ‘model’ regions. Duration: 60 months: Grant: 10,4 million euro.

Topic 5: Shortening the path to rare disease (RD) diagnosis by using newborn genetic screening and digital technologies. Scope: shorten the path to RD diagnosis by using newborn/paediatric (infants during their first weeks of life) genetic screening and, via application of advanced digital technologies that enable rare disease diagnosis/identification. The latter might require consolidation of existing fragmented efforts. Duration: 60 months: Grant: 11,9 million euro.

Topic 6: Behavioural Model of Factors Affecting Patient Adherence. Scope: identify the most significant factors which affect patient needs and adherence in a real-world context; evaluate existing models and either create an open access behavioural model or further develop an existing model; collect additional real-world data to refine the model; provide tools that will enable healthcare stakeholders to cost-effectively develop and implement solutions to address patient needs and improve adherence rates. Duration: 60 months: Grant: 5,9 million euro.

Eligible applicants

Legal entities established in a Member State or Country associated to Horizon 2020 that fall within one of the following categories: a) micro, small and medium-sized enterprises and other companies with an annual turnover of 500 million euro or less, the latter not being affiliated entities of companies with an annual turnover of more than 500 million euro; b) secondary and higher education establishments; c) non-profit organisations, including those carrying out research or technological development as one of their main objectives or those that are patient organisations.



Partnership criteria

The consortium must include at least three legal entities established in 3 EU Member States or Horizon 2020 associated countries.

Funding

Coverage of 100% of the project costs.

Deadlines

Stage 1 submission deadline: 29 September 2020

Stage 2 submission deadline: 17 March 2021

More information at

<https://www.imi.europa.eu/apply-funding/open-calls/imi2-call-23>